SAN ANTONIO — Fertility preservation and/or assisted reproductive technologies do not increase the risk for short-term cancer recurrence in young women with early hormone receptor (HR)-positive breast ...

Older women with high-risk hormone receptor-positive breast cancer showed no significant survival benefit from adjuvant chemotherapy 4 or 8 years later. The chemotherapy group experienced four times ...

Please provide your email address to receive an email when new articles are posted on . Preoperative breast MRI provides no benefit in stage I or II hormone receptor-negative breast cancer. Five-year ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. "We ...

HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is the most common subtype of breast cancer. It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer ...

– The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...

Not all metastatic breast cancers behave similarly in the body. Each subtype of breast cancer has distinct characteristics, which make them more likely to behave in ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sac-TMT reduced the risk of disease ...

—How often should liquid biopsy be done — and why? Heather McArthur, MD, clinical director of breast cancer at the University of Texas Southwestern Medical School weighs in. (0:40) The Current and ...

RP2D zovegalisib 600 mg BID plus fulvestrant yielded ORR 38.7% (31 evaluable) and tumor reduction in 80.6%, supporting mutant-selective PI3Kα targeting after endocrine resistance. Antitumor activity ...